Beijing Tong Ren Tang Chinese Medicine Company (3613) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
2 Dec, 2025Executive summary
Announcement discloses unaudited financial information for the nine months ended 30 September 2024, as published by the controlling shareholder Tong Ren Tang Technologies.
Reference is made to further details available on the Stock Exchange website.
Significant events and developments
Tong Ren Tang Technologies, the controlling shareholder, released its unaudited financials for the nine-month period.
Beijing Tong Ren Tang Company Limited, the ultimate controlling shareholder, will announce its own unaudited results on the Shanghai Stock Exchange by 30 October 2024.
Risk factors and uncertainties
Shareholders and potential investors are advised to exercise caution when dealing in the securities.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Beijing Tong Ren Tang Chinese Medicine Company
- Revenue and profit fell, but cash and equity rose; global expansion and innovation prioritized.3613
Q4 202520 Mar 2026 - Revenue and profit fell over 17% year-over-year, but liquidity and R&D investment stayed strong.3613Q2 20242 Dec 2025
- Revenue and profit rose, driven by expansion, innovation, and strong cash position.3613Q2 20252 Dec 2025
- Q1 2025 unaudited results released by the controlling shareholder; caution advised.3613Q1 20252 Dec 2025
- Controlling shareholder released unaudited 9-month 2025 results; parent to follow by 31 Oct.3613Q3 202531 Oct 2025
- Revenue up 5.7% but net profit down 10.4% as Overseas sales fell and costs rose.3613Q4 20245 Jun 2025